clinical trial · NCT06648772
Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·phase3·completed·n = 190
Plaque PsoriasisRoflumilast Cream 0.3%Vehicle cream
brief summary
This study is a multi-center, randomized, double-blind, vehicle-controlled phase III study to evaluate the efficacy, safety, and PK profile of roflumilast cream 0.3% in Chinese subjects ≥6 years of age with plaque psoriasis.
started
Nov 14, 2024
primary completion
Oct 13, 2025
completion
Oct 15, 2025
last updated
Jul 6, 2026
official title
A Multicenter, Randomized, Double-blind, Vehicle-controlled Phase 3 Clinical Study To Evaluate The Efficacy and Safety Of Roflumilast Cream 0.3% (Zoryve®) in the Treatment of Plaque Psoriasis In China
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol